Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: SETD2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy

Fig. 5

A Overall survival (OS) and progression free survival (PFS) curves of immune checkpoint inhibitor (ICI)-treated patients. B ORR rates and DCR rates of patients with PD-1/PD-L1 inhibitor monotherapy, or combined therapy with other drugs. C Mutation sites and types of SETD2 mutation in ICI-treated patients. D Response evaluation criteria in solid tumors (PR, partial response; SD, stable disease; PD, progression disease), cancer types, SETD2 mutation status, and treatment types of GenePlus ICI-treated patients. E SETD2 deleterious mutations are linked with improved survival outcome in the ICI-treatment cohort

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us